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Bone is one of the most frequent sites for metastasis in breast cancer patients often resulting in significant clinical morbidity and
mortality. Bisphosphonates are currently the standard of care for breast cancer patients with bone metastasis. We have shown
previously that doxycycline, a member of the tetracycline family of antibiotics, reduces total tumour burden in an experimental bone
metastasis mouse model of human breast cancer. In this study, we combined doxycycline treatment together with zoledronic acid,
the most potent bisphosphonate. Drug administration started 3 days before the injection of the MDA-MB-231 cells. When mice
were administered zoledronic acid alone, the total tumour burden decreased by 43% compared to placebo treatment.
Administration of a combination of zoledronic acid and doxycycline resulted in a 74% decrease in total tumour burden compared to
untreated mice. In doxycycline- and zoledronate-treated mice bone formation was significantly enhanced as determined by increased
numbers of osteoblasts, osteoid surface and volume, whereas a decrease in bone resorption was also observed. Doxycycline greatly
reduced tumour burden and could also compensate for the increased bone resorption. The addition of zoledronate to the regimen
further decreased tumour burden, caused an extensive decrease in bone-associated soft tissue tumour burden (93%), and sustained
the bone volume, which could result in a smaller fracture risk. Treatment with zoledronic acid in combination with doxycycline may
be very beneficial for breast cancer patients at risk for osteolytic bone metastasis.
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Bone is one of the most frequent sites for metastasis of breast and
prostate cancer. Bone metastases are often associated, especially in
breast cancer, with extensive osteolysis of mineralised collagenous
bone matrix (Kanis, 1995) and subsequent hypercalcaemia
resulting in significant clinical morbidity. Currently, there is no
adequate curative regimen for patients with bone metastasis. The
existing standard of care for the treatment of breast cancer-related
bone metastasis is the bisphosphonate family of drugs that
effectively inhibit the cancer-associated resorption. They are also
used as therapeutic agents in clinical disorders characterised by
increased osteolysis, such as osteoporosis (Berenson et al, 2001).
Unfortunately, treatment with bisphosphonates is not curative, but
randomised control trials have shown that zoledronate, the most
potent bisphosphonate, decreases the frequency of skeletal-related
events, delays the first occurrence of such an event, and reduces
pain in bone-metastatic breast cancer patients (Rosen et al, 2004;
Kohno et al, 2005). During the 2-year daily administration of oral
clodronate, one of the earlier bisphosphonates, to patients with
operable breast cancer without evidence of metastatic disease the
development of bone metastases is significantly reduced (Powles
et al, 2002). Therefore, preclinical evidence that zoledronate may
also be used to prevent the onset of bone metastasis would be very
worthwhile.
We have previously shown that doxycycline reduces the tumour
burden from breast cancer metastasis in nude mice substantially
(Duivenvoorden et al, 2002). Doxycycline has several properties
relevant for treatment of bone metastasis, as doxycycline can
inhibit tumour cell proliferation (Van den Bogert et al, 1983; Fife
and Sledge, 1995; Duivenvoorden et al, 1997) and MMP activity,
and accumulates at high concentrations in bone (Golub et al,
1991). We have also shown evidence to support the concept that
the reduction in tumour burden by doxycycline is likely due to its
properties as an inhibitor of tumour cell proliferation and that
doxycycline significantly increases several parameters of bone
formation (Duivenvoorden et al, 2002).
Bisphosphonates are stable pyrophosphate analogues that also
accumulate in bone and very effectively inhibit osteoclast-
mediated bone resorption. The most potent bisphosphonate is
zoledronate, which induces apoptosis of the osteoclast and
interferes with the operation of the ruffled border (Green, 2004).
In the present study, we combined doxycycline together with
zoledronic acid as a possible modality to prevent or reduce the
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stumour burden from bone metastasis using the experimental
breast cancer MDA-MB-231 mouse model.
MATERIALS AND METHODS
Cell line
The human breast adenocarcinoma MDA-MB-231 cell line
obtained from the American Type Culture Collection (Manassas,
VA, USA) was maintained in Dulbecco’s minimal essential
medium supplemented with 10% fetal bovine serum and
antibiotics (100Uml
 1 penicillin sodium, 100mgml
 1 strepto-
mycin sulphate and 0. 25mgml
 1 amphotericin B; Invitrogen
Canada Inc., Burlington, Ontario, Canada).
Animals
All protocols for animal studies were reviewed and approved by
the Animal Research Ethics Board of McMaster University
(Hamilton, Ontario, Canada). Per treatment group 10 female
inbred nude (Balb/c nu/nu) mice (Charles River, St. Constant,
Quebec, Canada) 5 weeks of age (15–20g) were used. Control
animals, not injected with tumour cells, were also included.
Intracardiac injections of MDA-MB-231 cells were done according
to Arguello et al (1988). Mice were anaesthetised by isoflurane
inhalation and the cells (0.1ml of cell suspension containing
1 10
5cells) were injected into the left ventricle of the heart using
a 26-gauge needle inserted percutaneously near the midline.
Twenty-eight days after injection of the cells, high-resolution
radiographic scans of all mice in the prone and lateral position
were taken under inhaled isoflurane anaesthesia with a Faxitron
X-ray system MX-20 (Faxitron X-ray Corporation, Wheeling, IL,
USA). The animals were killed and both tibiae, femora, and
humeri, and the spinal column were dissected, fixed in formalin,
decalcified, using Decalcifier I (Surgipath, Winnipeg, Manitoba,
Canada) and embedded in paraffin.
Treatment
Doxycycline-containing pellets (10mg per pellet with a timed-
release of 21 days; Innovative Research of America, Sarasota, FL,
USA) were implanted subcutaneaously 3 days before cancer cell
injections. Placebo pellets were used in control animals. At the
same time, pellets containing 0.25mg of 17b-estradiol (21 day-
release) were implanted in each animal. On the same day,
zoledronic acid (Novartis, Dorval, Quebec, Canada) treatment
was started, at a dose of 0.2mg per mouse of zoledronic acid (as
2mgml
 1 PBS), given as a subcutaneous injection. The zoledronic
acid injections were repeated nine times, every 2 days.
Histology and histomorphometry
Tumour burden in the long bones and the spinal column of each
mouse were measured using a stereological technique as described
before (Duivenvoorden et al, 2002). Longitudinal sections (thick-
ness 4mm) were cut through the middle part of the bone and
stained with haematoxylin and eosin (H&E). The total cumulative
tumour area per animal was calculated using a point grid (point
area of 0.02292mm
2) and expressed as bone tumour burden.
Histomorphometric measurements were performed on cancellous
area of the left and right femora starting 1mm below the
epiphyseal growth plate. Measurements were performed using a
digital color camera attached to a light microscope and Northern
Eclipse image-analysing software (Empix Imaging Inc., Mississau-
ga, Ontario, Canada). The following parameters were measured:
volume occupied by bone, and tumour as a fraction of the total
tissue volume (BV/TV and TuV/TV (%), respectively), number of
osteoclasts and osteoblasts per length of trabecular bone surface
(N.Oc/BS and N.Ob/BS (mm
 1), respectively), eroded bone
surface, active resorption surface beneath or in contact with
osteoclasts, and osteoid surface as a fraction of the trabecular bone
surface (ES/BS, Oc.S/BS, and OS/BS (%), respectively). To detect
tartrate-resistant acid phosphatase (TRAP) activity in the osteo-
clasts, naphthol AS-BI phosphate (Sigma-Aldrich, Oakville,
Ontario, Canada) was used according to van de Wijngaert and
Burger (1986).
Statistical analysis
Tumour burden data were tested for differences between means
using Student’s t-tests. Histomorphometric data were tested for
differences between medians using a two-tailed Mann–Whitney
test. Differences were considered significant at Po0.05.
RESULTS
Several bisphosphonates have been used in preclinical models of
breast cancer bone metastasis. Treatment of mice with ibandronate
(Hiraga et al, 2001), risedronate (Sasaki et al, 1995) or zoledronate
(Green et al, 2000) results in a reduction of 35, 50 and 80% in
osteolytic lesion area as determined by X-ray autoradiography,
respectively. Previously, we have shown that doxycycline also
significantly reduces tumour burden in the MDA-MB-231 breast
cancer bone metastasis model (Duivenvoorden et al, 2002). In this
study, we describe the effect of zoledronic acid on the skeletal
tumour burden in mice concurrently treated with doxycycline.
Doxycycline was administered to Balb/c nu/nu mice as described
previously (Duivenvoorden et al, 2002), resulting in a delivered
dose of approximately 15mgkg
 1day
 1 starting 3 days before
MDA-MB-231 cell injections. Zoledronate was administered at
0.2mg per mouse every 2 days starting at the same time as the
doxycycline treatment. We did not observe any adverse effects of
any treatment protocol in the mice over the study period of 28 days.
Six long bones (both femora, tibiae and humeri), and each vertebral
body of the spinal column of each mouse were screened for the
microscopical presence or absence of tumour. Previously, it has
been shown that the majority of the tumour burden occurs in these
bones (Sasaki et al, 1995; Duivenvoorden et al, 2002). Occasionally,
the maxillae and pelvic bone show presence of tumour.
Doxycycline alone and in combination with zoledronate
significantly reduced the tumour burden. Figure 1A shows the
total tumour burden as determined in the femora and spine. These
two bones contributed the most to the total tumour burden per
animal (Figure 1B). In the placebo group the total cumulative
tumour burden (for spine, femora, tibiae and humeri) per animal
amounted to 4.5971.34mm
2 in tumour-bearing animals (n¼15),
whereas the total tumour burden in the doxycycline group (n¼12)
was 2.2870.83mm
2, a significant reduction of 50%. In the group
of animals that received zoledronate alone (n¼10) the tumour
burden was 3.6271.05mm
2, a number that decreased to
2.1670.74mm
2 when doxycycline was added to the treatment
protocol (n¼6). The tumour burden in the latter group was also
significantly decreased when compared to the placebo-treated
animals. Interestingly, zoledronic acid effected primarily a
reduction in bone-associated soft tissue tumour burden, whereas
doxycycline decreased both the bone- and associated soft-tissue
tumour burden. Zoledronate caused a 93% reduction in soft-tissue
tumour burden, irrespective of doxycycline treatment, whereas the
total tumour burden was merely reduced by 74 and 43%, in the
presence or absence of doxycycline, respectively. The combination
treatment decreased the tumour burden of both bone and
associated soft tissue to a larger extent than either single treatment
alone (Figure 1A), although this trend did not reach statistical
significance. The numbers of mice per group ended up dissimilar,
even though, per repeated experiment, five mice per group were
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sinjected. The numbers also excluded mice that died very soon after
tumour cell injection and ones that did not develop tumours.
Moreover, the control and doxycycline-treated mice included mice
from previous experiments (Duivenvoorden et al, 2002).
Bone histomorphometry showed that both doxycycline and
zoledronate significantly increased several parameters of bone
formation in the femora, including osteoid volume (data not
shown), osteoid surface and the number of osteoblasts per bone
surface (see Table 1, Figure 2B and D). When zoledronic acid alone
was used, there was a dramatic and significant increase in bone
volume in control animals, which was maintained in the tumour-
bearing animals (Table 1). The addition of doxycycline to the
regimen of zoledronic acid sustained the increase in bone volume
and also induced a concomitant decrease in tumour volume even
though the difference did not reach significance.
The presence of breast cancer has a profound effect on bone.
Skeletal MDA-MB-231 tumours showed extensive marrow coloni-
sation, significant osteolysis, and cortical perforation. Whereas in
control animals, hardly any osteoclasts could be found, the
number of osteoclasts and the eroded bone surface increased
markedly in tumour-bearing bones (Figure 2A and C). In contrast,
the structure of the trabecular bone in mice treated with zoledronic
acid alone and in combination with doxycycline (Figure 3D and E)
seemed better preserved, even in the presence of tumour cells. The
mice treated with doxycycline in the presence or absence of
zoledronic acid both showed a significant increase in the osteoid
surface (Figure 2B); however, this effect could not be maintained in
the presence of tumour. Haematoxylin and eosin sections of the
femur (Figure 3) clearly show the osteolysis induced by the
presence of tumour. Sections stained for TRAP show the increased
presence of osteoclastic activity at the tumour–bone interface
(Figure 4). In the presence of tumour, we observed noticeable
osteolysis on H&E-stained sections and increased osteoclastic
activity at the tumour–bone interface after TRAP staining. We also
noticed less TRAP-positive osteoclasts present on the bone surface
in both zoledronic acid groups, in the presence or absence of
doxycycline (Figure 2C).
A major feature of breast cancer bone metastasis is the
uncoupling of bone remodeling. We also observed this phenom-
enon in tumour-bearing bones and show that doxycycline and
zoledronic acid can improve this to some level by increasing bone
formation. In doxycycline-treated tumour-bearing mice, the tissue
volume occupied by bone was significantly increased, 29.1%
compared to 22.7% in placebo (Table 1). The bone volume further
increased to 32.8 and 38.7% in animals treated with zoledronic
acid alone and in combination with doxycycline, respectively.
These represented levels of bone volume that were higher than in
control mice. This was accompanied by an increase in bone
formation parameters (number of osteoblasts (Figure 2D) and
osteoid surface (Figure 2B) and volume (Table 1)) and a
concomitant decrease in bone resorption parameters, such as
number of osteoclasts (Figure 2C) and eroded bone surface
(Figure 2A). Interestingly, in control mice, zoledronic acid alone
resulted in an increase in the number of both osteoclasts and
osteoblasts, suggesting an overall increase in bone remodeling,
even in the absence of tumour cells. Moreover, in autoradiographs
of mice treated with zoledronate, we also observed dense bone
nodules at the sites of rib articulation (data not shown). The









































































Figure 1 Effect on tumour burden in a mouse bone metastasis model of
human breast cancer (MDA-MB-231). Mice received a 21-day timed-
release pellets containing 10mg doxycycline 3 days before intracardiac
MDA-MB-231 injections. Other groups of mice received either zoledronic
acid (at 0.2mg per mouse s.c.) every 2 days alone or in combination with
doxycycline. A placebo group was also included. Mice were killed 28 days
after cell injection. Longitudinal sections of the spine and femora of tumour-
bearing animals (n¼15 in placebo group, n¼12 in doxycycline-group,
n¼10 in zoledronate-group, n¼6 in combination group,) were analysed
to determine (A) tumour burden in bone and bone-associated soft tissue
tumour burden and (B) average tumour bone burden per evaluated bone
(spine, humeri, femora and tibiae). Data represent means7s.e. of the
combined values of all animals in each of the groups in at least two separate
experiments. * Significantly different from corresponding placebo group
(Po0.05).
aSignificantly different from corresponding doxycycline-alone
group (Po0.05).
bSignificantly different from corresponding zoledronic acid-
alone group (Po0.05).
Table 1 Effect of treatment with doxycycline or zoledronate alone or combined on bone and tumour volume in mouse bone metastasis model of human
breast cancer (MDA-MB-231) as measured by bone histomorphometry on longitudinal sections of the femora
Bone volume BV/TV (%)
Placebo Doxycycline Zoledronic acid Doxycycline and zoledronic acid
Control animals 29.570.32 29.270.97** 37.071.79** 37.671.84**
a
Tumour-bearing animals 22.771.40* 29.172.69** 32.871.03** 38.775.15
Tumour volume TuV/TV (%)
Tumour-bearing animals 31.673.68 26.476.38 28.373.64 15.074.97
a
Data represent means7s.e. of the combined values of all animals in each of the groups in at least two separate experiments. *Significantly different from corresponding control
(no tumour) group (Po0.05). **Significantly different from corresponding placebo group (Po0.05).
aSignificantly different from corresponding doxycycline-alone group
(Po0.05).
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sirrespective of doxycycline treatment or the presence of tumour
cells.
DISCUSSION
Using the same bone metastasis model, zoledronate has been
shown to markedly reduce the area of osteolytic lesions as detected
by X-ray autoradiography, independent of time of administration
(concurrently with the tumour cell injections or after the
establishment of bone metastasis) (Peyruchaud et al, 2001) and
of the dose administered (0.2, 1 and 5mg per mouse; Green et al,
2000). When GFP-labelled MDA-MB-231 cells are used, the effect
of zoledronate on the fluorescence as a measure of the amount of
tumour cells is less pronounced than on the osteolytic lesion area
(Peyruchaud et al, 2001). Similarly, treatment with olpadronate,
another bisphosphonate, demonstrates that the tumour burden in
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Figure 2 Effect of doxycycline treatment on bone histomorphometric parameters in a mouse bone metastasis model of human breast cancer (MDA-MB-
231). Longitudinal sections of the femora were analysed to determine (A) eroded bone surface as a fraction of the trabecular bone surface (%), and (B)
osteoid surface as a fraction of the trabecular bone surface (%), (C) number of osteoclasts per mm trabecular bone surface, and (D) number of osteoblasts
per mm of trabecular bone surface. Data represent means7s.e. of the combined values of all animals in each of the groups in at least two separate
experiments (nX3). * Significantly different from corresponding control group (no tumour cells injected) (Po0.05). ** Significantly different from placebo
control animals (no tumour cells injected) (Po0.05).
oSignificantly different from placebo tumour-bearing animals (Po0.05).
aSignificantly different from
corresponding doxycycline-alone group (Po0.05).




Figure 3 (A) Histological appearance of the left femur of a control mouse (untreated, no cell injections) stained with H&E. (B–E) Histological
appearance of skeletal tumours in the left femora of mice injected with MDA-MB-231 cells after H&E staining. Mice were treated with (B) placebo, (C)
doxycycline, (D) zoledronic acid, or (E) with both doxycycline and zoledronic acid. (Original magnification  100, Bar ¼ 150mm). Bo, bone; GP, growth
plate; Tu, tumour.
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streated levels by the end of the 47-day treatment. During the same
time frame, radiography shows a sustained and extensive decrease
in osteolytic lesions (van der Pluijm et al, 2005), thus substantiat-
ing the primary mechanism of action of bisphosphonates as
anti-resorptive. We observed primarily a large reduction in bone-
associated soft tissue tumour burden (93%) after administration of
zoledronate. This is also supported by data using a 4T1/luc mouse
breast cancer model showing that zoledronic acid results in an
inhibition of visceral metastasis (Hiraga et al, 2004) and by Corey
et al (2003), who provided evidence to suggest that the inhibitory
effects of zoledronate may not only be associated to its effect on
osteolysis, but also on cancer cell proliferation and apoptosis.
When comparing both compounds, our results showed that
doxycycline induced a larger decrease in tumour burden, whereas
zoledronate was more capable of sustaining the bone volume, in
spite of an increase in bone resorption. Similar results were
reported using osteoblastic LuCaP23.1 or osteolytic PC-3 prostate
cancer cells injected into mouse tibiae. Zoledronic acid treatment
also induces a decrease in tumour volume and a concomitant
increase in bone volume (Corey et al, 2003). When we
administered both drugs the result was a substantial decrease in
tumour burden and a sustained bone volume. Future investiga-
tions will focus on potential effects on local concentrations of each
of the osteotropic drugs in the bone and on the specific targets of
both drugs. The main target of zoledronic acid appears to be the
induction of apoptosis (Corey et al, 2003; Quinn et al, 2005),
whereas doxycycline induces a G1 cell cycle arrest (Van den Bogert
et al, 1986). Hiraga et al (2001) describe a substantial increase in
apoptotic MDA-MB-231 cells in the bones of mice treated with
ibandronate, especially at the bone–tumour interface. Several
other mechanisms of action have also been suggested for both
drugs. In vitro, zoledronate has also been reported to stimulate
osteoprotegerin production in primary human osteoblasts
(Viereck et al, 2002), inhibit prostate cancer cell proliferation
(Corey et al, 2003), MMP activity (Boissier et al, 2000) and
adhesion to bone extracellular matrix (Boissier et al, 1997).
Whereas the current study clearly demonstrates the benefit of
combined treatment when both drugs are administered simulta-
neously starting 3 days before cell injections, future experiments
will include sequential administration, and starting several weeks
after the cell injections. This will help to determine whether
doxycycline could also be beneficial for patients with already
established bone metastasis and who are currently receiving
zoledronic acid and vice versa. In conclusion, doxycycline greatly
reduced tumour burden and could also compensate for the
increased bone resorption frequently associated with bone
metastasis from breast cancer. The addition of zoledronate to the
treatment regimen further decreased tumour burden and effected
an extensive decrease in bone-associated soft tissue tumour
burden, independent of doxycycline treatment. Moreover, the
combination also sustained bone volume, which could greatly
reduce the risk of fracture. Treatment with zoledronic acid in
combination with doxycycline may be very beneficial for breast
cancer patients at risk for osteolytic bone metastasis.
ACKNOWLEDGEMENTS
We thank the Canadian Breast Cancer Research Initiative and
Canadian Institutes of Health Research for financial support. We
are indebted to Scott Su and Dr S Lhota ´k for excellent technical
assistance.
REFERENCES
Arguello F, Bages RB, Frantz CN (1988) A murine model of experimental
metastasis in bone and bone marrow. Cancer Res 48: 6876–6881
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer
R, Kuross SA, Lipton A, Seaman JJ (2001) Zoledronic acid reduces
skeletal-related events in patients with osteolytic metastases. Cancer 91:
1191–1200
Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel




Figure 4 (A) Histological appearance of the left femur of a control mouse (untreated, no cell injections) stained for TRAP. No osteoclasts were observed.
(B–E) Histological appearance of skeletal tumours in the left femora of mice injected with MDA-MB-231 cells showing TRAP-positive osteoclasts
(arrowheads). Mice were treated with (B) placebo, (C) doxycycline, (D) zoledronic acid or (E) with both doxycycline and zoledronic acid. (Original
magnification  400, Bar¼20mm). Bo, bone; Tu, tumour; arrowheads, osteoclasts.
Doxycycline and zoledronate reduce total tumour burden
WCM Duivenvoorden et al
1530

























sbreast and prostate carcinoma cell invasion, an early event in the
formation of bone metastases. Cancer Res 60: 2949–2954
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD,
Clezardin P (1997) Bisphosphonates inhibit prostate and breast cancer
carcinoma cell adhesion to unmineralized and mineralized bone
extracellular matrices. Cancer Res 57: 3890–3894
Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL
(2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and
osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295–306
Duivenvoorden WCM, Hirte HW, Singh G (1997) Use of tetracycline as an
inhibitor of matrix metalloproteinase activity secreted by human bone-
metastasizing cancer cells. Invasion Metastasis 17: 312–322
Duivenvoorden WCM, Vukmirovic-Popovic S, Lhotak S, Seidlitz E, Hirte
HW, Tozer RG, Singh G (2002) Doxycycline decreases tumor burden
in a bone metastasis model of human breast cancer. Cancer Res 62:
1588–1591
Fife RS, Sledge Jr GW (1995) Effects of doxycycline on in vitro growth,
migration, and gelatinase activity of breast carcinoma cells. J Lab Clin
Med 125: 407–411
Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR
(1991) Tetracyclines inhibit connective tissue breakdown: new thera-
peutic implications for an old family of drugs. CRC Crit Rev Oral Biol
Med 2: 297–321
Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9: 3–13
Green JR, Gschaidmeier H, Yoneda T (2000) Zoledronic acid potently
inhibits tumour-induced osteolysis in two models of breast cancer
metastasis to bone. Ann Oncol 11: 14
Hiraga T, Williams PJ, Mundy GR, Yoneda T (2001) The bisphosphonate
Ibandronate promotes apoptosis in MDA-MB-231 human breast cancer
cells in bone metastases. Cancer Res 61: 4418–4424
Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T (2004) Zoledronic acid
inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Clin Cancer Res 10: 4559–4567
Kanis JA (1995) Bone and cancer: pathophysiology and treatment of
metastases. Bone 17: 101S–105S
Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T,
Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly
reduces skeletal complications compared with placebo in Japanese
women with bone metastases from breast cancer: a randomized, placebo-
controlled trial. J Clin Oncol 23: 3314–3321
Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P
(2001) Early detection of bone metastases in a murine model using
fluorescent human breast cancer cells: application to the use of the
bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
J Bone Miner Res 16: 2027–2034
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist
K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E,
Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized,
placebo-controlled trial of clodronate in patients with primary operable
breast cancer. J Clin Oncol 20: 3219–3224
Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E (2005)
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests
that zoledronic acid inhibits prostate cancer in bone by indirect
mechanisms. Prostate Cancer Prostatic Dis 8: 253–259
Rosen LS, Gordon DH, Dugan Jr W, Major P, Eisenberg PD, Provencher L,
Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004)
Zoledronic acid is superior to pamidronate for the treatment of bone
metastases in breast carcinoma patients with at least one osteolytic
lesion. Cancer 100: 36–43
Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR,
Yoneda T (1995) Bisphosphonate risedronate reduces metastatic human
breast cancer burden in bone in nude mice. Cancer Res 55: 3551–3557
van de Wijngaert FP, Burger EH (1986) Demonstration of tartrate-resistant
acid phosphatase in un-decalcified, glycolmethacrylate-embedded mouse
bone: a possible marker for (pre)osteoclast identification. J Histochem
Cytochem 34: 1317–1323
Van den Bogert C, Dontje BH, Kroon AM (1983) Arrest of in vivo growth of
a solid Leydig cell tumor by prolonged inhibition of mitochondrial
protein synthesis. Cancer Res 43: 2247–2251
Van den Bogert C, van Kernebeek G, de Leij L, Kroon AM (1986) Inhibition
of mitochondrial protein synthesis leads to proliferation arrest in the G1-
phase of the cell cycle. Cancer Lett 32: 41–51
van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A,
Thalmann GN, Papapoulos SE, Cecchini MG (2005) Interference with the
microenvironmental support impairs the de novo formation of bone
metastases in vivo. Cancer Res 65: 7682–7690
Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C,
Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid
stimulate osteoprotegerin production by primary human osteoblasts.
Biochem Biophys Res Commun 291: 680–686
Doxycycline and zoledronate reduce total tumour burden
WCM Duivenvoorden et al
1531
British Journal of Cancer (2007) 96(10), 1526–1531 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s